Recommendations on the Use of 18F-FDG PET in Oncology
By J. Fletcher, B. Djulbegovic, H. Soares, B. Siegel, V. Lowe, G. Lyman, R. Coleman, R. Wahl, J. Paschold, N. Avril and 6 more. Journal of Nuclear Medicine, 2008
1,016 citations recorded by the source corpus.
Subfields: Oncology, Radiology, Nuclear Medicine and Imaging, Surgery
View Paper: https://www.semanticscholar.org/paper/120e1c99d017100cab3eca286a76a9a0faea6fa0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Radiology, Nuclear Medicine and Imaging
- G. Parker
- Ronald Boellaard
- Jacques-Donald Tournier
- Alan Connelly
- Fernando Calamante
- Daniel C. Alexander
- Heidi Johansen-Berg
Citations in the corpus
- Metabolic heterogeneity in human lung tumors (2016, neutral): “The most widely used form of metabolic imaging is fluoro-2-deoxyglucose positron emission tomography (FDG-PET), which capitalizes on enhanced glucose uptake in tumors (Fletcher et al., 2008).”
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 (2009, background): “An excellent overview is given in [ 6 ], but these indications are constantly changing and require updating with time.”
- Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome (2014, background): “The presence of abnormal glycolysis in part of a tumor using SUVmax is used widely to stage andmonitor response in several malignant tumors (25).”
- Lactate metabolism in human lung tumors (2017, neutral): “18fluoro-2-deoxyglucose positron emission tomography (FDG-PET) utilizes the propensity of many solid tumors to take up and retain glucose, providing imaging contrast with adjacent tissue (Fletcher et al., 2008).”